Navigation Links
Iomai Reports 'Going Concern' Qualification in 10-K
Date:3/28/2008

GAITHERSBURG, Md., March 28 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced, in compliance with NASDAQ marketplace rules, that the independent audit report included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2008 for the fiscal year ended December 31, 2007 contained a "going concern" qualification. This disclosure is required under NASDAQ marketplace rules and does not represent any change to the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and filed on March 27, 2008 with the SEC.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.


'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
2. Iomai CEO to Speak at Cowen and Company Health Care Conference on Monday, March 17
3. Iomai Study Shows Self-Applied Travelers Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch
4. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
5. Hospital for Special Surgery Reports Scores on HCAHPS Survey
6. PreMD Reports Fiscal 2007 Results
7. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
8. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
9. Spheris Reports Fourth Quarter and Year-End 2007 Results
10. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
11. QMed, Inc. Reports Year-End and Fourth Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... , ... In the United States, 20 million women and 10 million men ... feel shame for having struggled with an eating disorder as well as common co-occurring ... in Life After an Eating Disorder” -- to be featured at this year’s iaedp ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... ... , ... Doctor C LLC, a company based out of Arizona that focuses ... the marketing and distribution of its product, The Right C. , The Right C ... than traditional vitamin C supplements. At the trade show, Doctor C had the opportunity ...
(Date:1/20/2017)... ... 20, 2017 , ... ATP Science, an Australian-based company focused ... the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding meetings ... of supplements that keep the body functioning at its peak performance by providing ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
(Date:1/19/2017)... 19, 2017 James ... & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European ... touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... , January 19, 2017 ... Otsuka in the Milner Therapeutics Consortium   ... in Cambridge   ... PFE ) as a partner to the ... Consortium, which enables the efficient transfer of materials between ...
Breaking Medicine Technology: